Unruptured cerebral arteriovenous malformations: to treat or not to treat.

نویسنده

  • Kevin M Cockroft
چکیده

See related article, pages 1243–1247 As noninvasive brain imaging for sometimes dubious indications becomes more and more ubiquitous, greater numbers of asymptomatic lesions are being found and management decisions are being required. Cerebral arteriovenous malformations (AVM) represent a particularly challenging subset of these lesions, given their overall low incidence and the high frequency with which some form of multimodality treatment may be required for complete obliteration. In order to make an educated decision regarding therapy, a thorough understanding of the natural history is needed, but not always available. In the case of intracranial AVM, a combination of retrospective and prospective studies have yielded a generally accepted bleed risk of 2% to 4% per year with an associated neurological morbidity of 20% to 30% and mortality of 10% to 30% with each bleed.1–12 Unfortunately, all of these reports constitute level V evidence and suffer from the usual methodological problems of case series, including selection bias, treatment bias and inconsistent follow-up. In this issue of Stroke, Choi et al13 update these outcome statistics using data prospectively entered into the Columbia AVM Databank from 1989 to 2004. The authors examine the clinical outcome after first and recurrent hemorrhage in patients with untreated cerebral AVM. Rankin Score (RS) and National Institutes of Health Stroke Score (NIHSS), both acutely and after follow-up, were collected. Outcome results were also stratified according to the anatomical location of the initial hemorrhage (nonparenchymatous or parenchymatous). In addition, outcome after parenchymatous hemorrhage was compared with outcome data from survivors of non–AVM-related intracerebral hemorrhage from the Northern Manhattan Study (NOMAS). The study was not designed to provide data regarding the de novo risk of AVM hemorrhage or the risks of treatment. After their initial hemorrhage, the majority of patients (72%) had an RS of 2 and 61% of patients had NIHSS scores of 0 or 1. In a multivariate analysis, parenchymatous AVM hemorrhage was an independent predictor of an unfavorable outcome (NIHSS score 2), whereas age, gender, race, and AVM size showed no significant effect. Follow-up data were provided only for untreated patients and for treated patients up to the last available assessment before treatment. A median of 55 days (mean of 657 days) follow-up was achieved. Neurological outcome in terms of NIHSS was similar after a second hemorrhage. However, disability as measured by RS was significantly worse (RS mean 2.7 1.4 versus 2.0 1.4) after a second hemorrhage. One patient died after a recurrent bleed, but 40% demonstrated some clinical improvement. In comparison to NOMAS patients, AVM patients had a significantly better clinical outcome (median NIHSS 1 versus 12). However, AVM patients were also significantly younger and more likely to be white. Although a valiant effort, Choi et al’s13 report suffers from many of the same methodological concerns as previously published AVM natural history data, with selection/referral bias and treatment bias being perhaps the most significant. As the authors point out, there was an average delay of 7 days between the index event and first evaluation among the AVM patients. This speaks to the potential for systematic referral bias seen in most case series from tertiary care centers. From the initial RS and NIHSS scores it would appear that those patients considered viable were certainly transferred, but it is quite conceivable that other more devastated patients may not have been referred. Follow-up data were provided only for untreated patients and for treated patients up to the last available assessment before treatment. Because follow-up for treated patients is censored at the time of treatment, it becomes important to know the selection criteria used for treatment. Without this information it is not possible to determine whether treated patients were considered to be at substantially higher risk for rebleeding, whether they were simply the ones with the most treatable/accessible lesions, or both. Depending on the bias in this area, results may be influenced in either direction. Regardless of one’s view of the study biases, the documented rebleed rate and clinical outcome remain concerning. In the short follow-up period examined (average 1.8 years), the crude annual rebleed rate was 7% and disability was significantly increased after subsequent hemorrhage. If one takes the average age of the AVM population from this study of 37 years of age and uses a life expectancy of 39 additional years (Period Life Table, Actuarial Publications, http://www.ssa.gov/OACT/STATS/ table4c6.html), the cumulative risk of rehemorrhage is 94%. Even if one assumes the risk of rebleeding stabilizes at 4% per year, the cumulative risk of rehemorrhage over 39 years is 78%. Clearly, this does not suggest a benign future for patients with a history of AVM-related intracranial hemorrhage. In terms of clinical status, a careful examination of the outcome information provided is crucial. Of the 2 “outcome” measures provided, it is the RS that provides the most critical information. After all, it is the patient’s disability, or lack thereof, which will determine their functional status, not their neurological deficit per se. As The opinions in this editorial are not necessarily those of the editors or of the American Heart Association. From the Department of Neurosurgery, Penn State MS Hershey Medical Center, Hershey, Pa. Correspondence to Kevin M. Cockroft, Department of Neurosurgery, Penn State MS Hershey Medical Center, PO Box 850, Hershey, PA 17033. E-mail [email protected] (Stroke. 2006;37:1148-1149.) © 2006 American Heart Association, Inc.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Risk Reduction of Cerebral Stroke After Stereotactic Radiosurgery for Small Unruptured Brain Arteriovenous Malformations.

BACKGROUND AND PURPOSE A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) indicated the superiority of medical management in reducing the risks for strokes and other neurological deficits over observation alone. The aim of our study was to verify the rationale for stereotactic radiosurgery (SRS) for small unruptured arteriovenous malformation. METHODS A retrospective r...

متن کامل

Radiosurgery for Cerebral Arteriovenous Malformations in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)-Eligible Patients

Cerebral arteriovenous malformations (AVMs) are rare vascular lesions detected at an annual incidence of ≈1 in 100 000. The natural history of unruptured AVMs is more benign than ruptured ones, primarily because of their lower hemorrhage risk. The only currently available strategy for AVM management that provides durable relief from the risk of hemorrhage is complete obliteration of the nidus. ...

متن کامل

Radiosurgery for Cerebral Arteriovenous Malformations in A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)-Eligible Patients: A Multicenter Study.

BACKGROUND AND PURPOSE The benefit of intervention for patients with unruptured cerebral arteriovenous malformations (AVMs) was challenged by results demonstrating superior clinical outcomes with conservative management from A Randomized Trial of Unruptured Brain AVMs (ARUBA). The aim of this multicenter, retrospective cohort study is to analyze the outcomes of stereotactic radiosurgery for ARU...

متن کامل

Embolization of feeding arteries and symptom alleviation of mixed dural-pial arteriovenous malformations

Background: To examine whether embolization of dural or pial blood supply branch is more efficient for symptom alleviation for unruptured mixed dural-pial arteriovenous malformations (DPAVMs). Methods: We retrospectively reviewed 30 DPAVM patients from a database of 425 consecutive cerebral arteriovenous malformation (CAVM) patients who underwent endovascular embolization between January 2010 a...

متن کامل

A perfect storm: how a randomized trial of unruptured brain arteriovenous malformations' (ARUBA's) trial design challenges notions of external validity.

The management of unruptured brain arteriovenous malformations (BAVMs) is controversial and uncertainties exist as to how best to care for these patients. The A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA)1 study attempts to shed light on some of these issues. However, the complexity of the disease process, the considerable variation in treatment options, and the tri...

متن کامل

Long term effects of Gamma knife Radiosurgery for treatment of cerebral arteriovenous malformations

 Abstract Background: The Gamma Knife Radiosurgery (GKR) is an established management option for Cerebral Ar-teriovenous Malformations (AVMS). Therapeutic benefits of radiosurgery for arteriovenous malformations are complete obliteration of nidus with minimal neurological deficit. Methods: Radiosurgery was performed between February 2003 and April 2010 at Kamraniye day clinic, Teh-ran, Iran, us...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Stroke

دوره 37 5  شماره 

صفحات  -

تاریخ انتشار 2006